Biotech Drug Report Generated Jul 14, 2026

PMN310

PMN·ProMIS Neurosciences Inc.

BULLISH

Drug Impact Rating7/10

Trial Phase: Phase 1b
Time to Market: Years away — Phase 1b enrollment complete, but Phase 2/3 trials, if initiated, would take multiple years. Best-case earliest approval likely 2029+.
Why 7/10: The next hard catalyst is the blinded 6-month interim biomarker/safety analysis from the Phase 1b PRECISE-AD trial, indicated as "in the coming weeks" per the July 14, 2026 AAIC press release, with unblinded 12-month topline results expected Q4 2026. PMN310 is the company's only clinical-stage asset and drives essentially all of PMN's valuation. A Phase 1b interim readout is not a pivotal binary, but at a single-asset company with imminent news, the share-price move potential is high — hence a 7.

Actionable Insight BULLISH

The Phase 1b PRECISE-AD interim analysis (blinded 6-month biomarker data) is the critical near-term catalyst, expected within weeks. Positive biomarker signals (Aβ oligomer reduction, pTau) could send the stock sharply higher given the low float and ~$12.80 share price vs. ~$32 mean analyst target. However, a Phase 1b readout is not de-risking enough to guarantee Phase 2/3 success, and the competitive Alzheimer's landscape is crowded with approved drugs (lecanemab, donanemab).

Price Chart

Loading chart...

Executive Summary

PMN310 is ProMIS Neurosciences' lead (and only clinical-stage) asset — a monoclonal antibody designed to selectively target toxic amyloid-beta oligomers in Alzheimer's disease. Phase 1a data showed a favorable safety profile and dose-dependent target engagement in CSF. The Phase 1b PRECISE-AD trial (144 patients enrolled, 3 doses vs. placebo over 12 months) completed enrollment in December 2025. A blinded 6-month interim analysis is expected imminently (noted as "coming weeks" in a July 14, 2026 AAIC press release), with final topline data by end of 2026. The FDA granted Fast Track designation in July 2025. The company raised ~$75M upfront (up to $175M with warrants) via PIPE in January 2026 to fund development. Analyst consensus is Strong Buy (9:1 bullish) with a mean price target of ~$32, implying ~150% upside from ~$12.80. Key risks: Phase 1b interim results could disappoint, the Alzheimer's market is intensely competitive with approved plaque-directed antibodies, and ProMIS has no revenue or other clinical-stage programs to fall back on.

How It Works

PMN310 is a lab-engineered antibody (a type of immune protein) designed to selectively latch onto and clear the most toxic form of the amyloid-beta protein — small clumps called "oligomers" — that are thought to drive Alzheimer's disease. Unlike the approved Alzheimer's drugs lecanemab and donanemab, which bind to amyloid plaques (larger clumps) and can cause brain swelling/bleeding (ARIA), PMN310 is designed to skip the plaques and go after only the soluble toxic oligomers, which the company believes could mean better efficacy with fewer safety risks.

Trial Status

Phase 1a (single ascending dose in 40 healthy volunteers) completed October 2024 — well-tolerated, dose-dependent CNS penetration and proof of target engagement via Aβ oligomer reduction in CSF (reported at AAIC July 2026). Phase 1b PRECISE-AD trial (NCT06750432) enrolled 144 patients (vs. 128 target) by December 2025 — randomized, double-blind, placebo-controlled, three dose cohorts (5, 10, 20 mg/kg IV q28d for 12 months). Blinded 6-month interim analysis imminent (Q3 2026); final 12-month unblinded topline expected Q4 2026.

The Two-Sided Case

▲ Bull Case6

Selective oligomer-targeting mechanism is differentiated from approved plaque-directed antibodies (lecanemab, donanemab); may reduce ARIA brain-swelling risk, a major safety limitation of existing drugs

Phase 1a data demonstrated dose-dependent BBB penetration and first-in-human evidence of Aβ oligomer reduction in CSF (presented at AAIC July 2026) — a pharmacodynamic proof-of-mechanism no competitor has shown at this stage

PRECISE-AD 144 patients exceeds original 128-patient target, suggesting enthusiasm from patients and physicians; 3 dose levels vs. placebo with 12-month treatment and comprehensive biomarker panel (pTau217, pTau243, synaptic markers)

Analyst consensus is Strong Buy (9 total: 2 Strong Buy, 7 Buy, 1 Hold); mean price target ~$32.21 vs. ~$12.80 current — ~150% implied upside. HC Wainwright (Buy) has top-tier 67% accuracy on the name

Institutional heavyweights are accumulating: Janus Henderson ($16.4M), Wellington Management ($8.8M), Woodline Partners ($5.0M) as of Q1 2026 13F filings

$75M PIPE (Jan 2026, up to $175M with warrants) should extend runway into 2028 and fund through key catalysts

▼ Bear Case5

Phase 1b is still an early-stage safety/biomarker trial — no efficacy conclusions can be drawn; the blinded interim is not a pivotal readout. The stock could sell off on any cautious language even if data is neutral

Alzheimer's is an intensely competitive field: lecanemab (Eisai/Biogen) and donanemab (Lilly) are already approved. Acumen's sabirnetug — another oligomer-selective antibody — is in Phase 2 with topline due late 2026 and could beat PMN310 to market

No revenue, no approved products, and heavy cash burn (FY2026 EPS est. -$8.24). The company is entirely reliant on PMN310 — any setback would be existential

Stock is volatile: 52-week range $6.27–$39.75 reflects extreme binary sentiment swings. Shares popped ~150% on the July 2025 Fast Track news and could give up gains fast on any negative data

The Fast Track designation accelerates FDA interactions but does not guarantee approval or shorten trial requirements

Upcoming Catalysts

Blinded 6-month interim biomarker/safety data from PRECISE-AD Phase 1b — expected 'in the coming weeks' per July 14, 2026 (AAIC press release; previously Q2 2026 guidance)
Final unblinded 12-month topline results from PRECISE-AD — expected Q4 2026
Competitor readout: Acumen's sabirnetug (ACU193) Phase 2 ALTITUDE-AD topline data — late 2026. Positive data would validate the oligomer-selective class and boost PMN310; negative data would likely weigh on PMN by association
Potential partnership or licensing discussions if interim data is strong

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ProMIS Neurosciences Inc. Press Release PMN ·Originating report

Sources · 11

Hover a chip for the title

1 promisneurosciences.com2 globenewswire.com3 globenewswire.com4 biospace.com5 clinicaltrials.gov6 biospace.com7 promisneurosciences.com8 sec.gov9 trial.medpath.com10 sec.gov11 tradingview.com